Spots Global Cancer Trial Database for A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

Official Title: A Multi-Institutional Phase II Study Evaluating Surrogate Biomarkers of Response to Short Term Oral Vorinostat and Tamoxifen in Women With Newly Diagnosed Breast Cancer

Study ID: NCT01194427

Conditions

Stage I Breast Cancer

Stage II Breast Cancer

Stage III Breast Cancer

Invasive Breast Cancer

Interventions

Vorinostat and Tamoxifen

Study Description

Brief Summary: This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The investigators will do this by comparing tissues from the original breast biopsy to tissues obtained after taking vorinostat and tamoxifen for 2 weeks.

Detailed Description: Key eligibility criteria include: * Newly diagnosed invasive breast cancer awaiting surgery or neoadjuvant (preoperative) treatment * No use of hormone contraceptives or replacement therapy within 30 days prior to the diagnostic breast cancer biopsy (unless willing to have an additional biopsy prior to starting the study) * No prior or current use of any therapy to treat the current breast cancer.